提醒成功

搜索
产品规范 | |
---|---|
Type | In Vivo - Reseach Grade Antibody |
Host | CHO cells |
catalog# | B00045 |
Application | Flow cytometry, animal model study |
Aliases | B29, IGB, Ig-beta |
Size/Concentration | 1mg/5mg/20mg |
Isotype | Human IgG1 kappa |
Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Human CD79B |
Formulation | PBS, pH 7.4 |
Description |
---|
What is polatuzumab biosimilar research grade? Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab. |
Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody B00045
规格:
- 1mg
- 5mg
- 20mg
数量:
-
+
说明书:


¥1300
-
咨询
-
收藏

